

Substitute for form 1449/PTO
(Revised 07/2007)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/657,550
Filing Date	September 4, 2003
First Named Inventor	Chaudry
Art Unit	1616
Examiner Name	J. H. Alstrum Acevedo
Attorney Docket Number	048765/277062

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
/J.H.A.A./	10	EP 0 385 445 A2	09-05-1990	Horikoshi		
	11	JP 1-100120 A	04-18-1989	Beecham Group PLC		*
	12	JP 03-165833	07-17-1991	Horikoshi et al.		* (relates to EP 0 385 445)
	13	JP 5-506642	09-30-1993			*
	14	JP 07-053358	02-28-1995	Teijin Ltd.		*
	15	JP 11-130659 A	05-18-1999	Teijin Ltd.		*
/J.H.A.A./	16	JP 11-514979 A	12-21-1999			(relates to WO 97/08950 A1)
	17	JP 2001-002589	01-09-2001	Teijin Ltd.		*
	18	JP 2000-508675 A	07-11-2000			*
	19	JP 2001-520188 A	10-30-2001			*
	20	JP 2001-523638	11-27-2001			*
	21	JP 2002-539154	11-19-2002			*
/J.H.A.A./	22	JP 2003-506396	02-18-2003	Glaxo Wellcome Kabushiki Kaisha		* (relates to WO 01/10409 A1)
	23	JP 2005-506369	03-03-2005			* (relates to WO 03/035062)
/J.H.A.A./	24	JP 2005-503378	02-23-2005			* (relates to WO 03/013434)
/J.H.A.A./	25	WO 97/08950 A1	03-13-1997	Fuisz Technologies, Ltd.		
	26	WO 00/12063 A1	03-09-2000	Teijin Ltd. et al.		*
/J.H.A.A./	27	WO 01/10409 A1	02-15-2001	Glaxo Wellcome Kabushiki Kaisha		
/J.H.A.A./	28	WO 01/13885 A1	03-01-2001	Norton Healthcare Ltd.		
/J.H.A.A./	29	WO 01/78743 A1	10-25-2001	Glaxo Group Limited		

Examiner Signature	/James Alstrum Acevedo/	Date Considered	01/20/2011
--------------------	-------------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. LEGAL02/32241221v1

Submitted October 26, 2010

Substitute for form 1449/PTO
(Revised 07/2007)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/657,550
Filing Date	September 4, 2003
First Named Inventor	Chaudry
Art Unit	1616
Examiner Name	J. H. Alstrum Acevedo
Attorney Docket Number	048765/277062

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
/J.H.A.A./	30	WO 02/055136 A2	07-18-2002	Nephros Therapeutics, Inc.		
/J.H.A.A./	31	WO 02/072066 A1	09-19-2002	Pharmacia & Upjohn company		
/J.H.A.A./	32	WO 03/013434 A2	02-20-2003	Genomed, LLC		
/J.H.A.A./	33	WO 2003/020219 A2	03-13-2003	Sinus-Pharma Inc		
	34	WO 03/035062 A1	05-01-2003	Sanofi-Synthelabo		*
		*Abstract only				

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
/J.H.A.A./	35	Office Action for Japanese Application No. 2006-504903 dated August 4, 2010	
/J.H.A.A./	36	Office Action for Japanese Application No. 2006-504901 dated August 4, 2010	
/J.H.A.A./	37	Office Action for Japanese Application No. 2006-504902 dated August 4, 2010	
/J.H.A.A./	38	Office Action for Japanese Application No. 2006-516000 dated September 8, 2010	

Examiner
Signature

/James Alstrum Acevedo/

Date
Considered

01/20/2011

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. LEGAL02/32241221v1

Submitted October 26, 2010